Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current perspectives in cancer proteomics.

Literature DB >> 12405262

Current perspectives in cancer proteomics.

Abstract

Proteome technology has been used widely in cancer research and is a useful tool for the identification of new cancer markers and treatment-related changes in cancer. This article details the use of proteome technology in cancer research, and laboratory-based and clinical cancer research studies are described. New developments in proteome technology that enable higher sample-throughput are evaluated and methods for enhancing conventional proteome analysis (based on two-dimensional electrophoresis) discussed. The need to couple laboratory-based proteomics research with clinically relevant models of the disease is also considered, as this remains the next main challenge of cancer-related proteome research.

Entities: Disease

Mesh：

Substances：
Proteome

Year: 2002 PMID： 12405262 DOI： 10.1385/MB:22:2:139

Source DB: PubMed Journal: Mol Biotechnol ISSN： 1073-6085 Impact factor: 2.695

110 in total

Review 1. Proteomics: a new approach to the study of disease.

Authors: G Chambers; L Lawrie; P Cash; G I Murray
Journal: J Pathol Date: 2000-11 Impact factor: 7.996

2. A database of protein expression in lung cancer.

Authors: J M Oh; F Brichory; E Puravs; R Kuick; C Wood; J M Rouillard; J Tra; S Kardia; D Beer; S Hanash
Journal: Proteomics Date: 2001-10 Impact factor: 3.984

3. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry.

Authors: T S Lewis; J B Hunt; L D Aveline; K R Jonscher; D F Louie; J M Yeh; T S Nahreini; K A Resing; N G Ahn
Journal: Mol Cell Date: 2000-12 Impact factor: 17.970

4. Two epidemiological inquiries into the incidence of bladder tumors in industrial workers.

Authors: C A Veys
Journal: J Natl Cancer Inst Date: 1969-07 Impact factor: 13.506

5. Marker polypeptide differences between spontaneous strongly and weakly metastatic cancer cells identified by 2-dimensional gel electrophoresis.

Authors: I A Grimstad; A K Thorsrud; J Varani; P A Ward; E Jellum
Journal: Int J Cancer Date: 1988-04-15 Impact factor: 7.396

6. Two-dimensional database of a Burkitt lymphoma cell line (DG 75) proteins: protein pattern changes following treatment with 5'-azycytidine.

Authors: F Poirier; M Pontet; V Labas; J P le Caër; N Sghiouar-Imam; M Raphaël; M Caron; R Joubert-Caron
Journal: Electrophoresis Date: 2001-05 Impact factor: 3.535

Review 7. Proteome and glycosylation mapping identifies post-translational modifications associated with aggressive breast cancer.

Authors: M V Dwek; H A Ross; A J Leathem
Journal: Proteomics Date: 2001-06 Impact factor: 3.984

8. Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma.

Authors: C Sarto; S Frutiger; F Cappellano; J C Sanchez; G Doro; F Catanzaro; G J Hughes; D F Hochstrasser; P Mocarelli
Journal: Electrophoresis Date: 1999-11 Impact factor: 3.535

Current perspectives in cancer proteomics.

Review 1. Proteomics: a new approach to the study of disease.

2. A database of protein expression in lung cancer.

3. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry.

4. Two epidemiological inquiries into the incidence of bladder tumors in industrial workers.

5. Marker polypeptide differences between spontaneous strongly and weakly metastatic cancer cells identified by 2-dimensional gel electrophoresis.

6. Two-dimensional database of a Burkitt lymphoma cell line (DG 75) proteins: protein pattern changes following treatment with 5'-azycytidine.

Review 7. Proteome and glycosylation mapping identifies post-translational modifications associated with aggressive breast cancer.

8. Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma.

9. Structures of disease-specific serum alpha-fetoprotein isoforms.

10. Expression of tropomyosin isoforms in benign and malignant human breast lesions.

Review 1. Proteomic analysis in multiple myeloma research.

2. Breast cancer and protein biomarkers.

Review 3. Strategies for analysis of the glycosylation of proteins: current status and future perspectives.